The Broker Innovation Lab celebrates brokers and other benefits stakeholders who have embraced the changing marketplace to position themselves and their business for future success
Observers say that while capping the cost of insulin at $35 a month benefits consumers, it doesn't strengthen Lilly's legal arguments since the company and others raised list prices by 150% over five years, alleges one lawsuit.
"I wholeheartedly disagree with noncompetes at any level," said Sameer Baig, a Florida doctor who says huge health care companies use them to get the upper hand on physicians who might otherwise leave.